Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-61.11%)
USD 0.0
(-61.11%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 32.4 Million USD | -14.62% |
| 2022 | 37.95 Million USD | -49.25% |
| 2021 | 74.78 Million USD | -33.75% |
| 2020 | 112.88 Million USD | -5.12% |
| 2019 | 118.97 Million USD | -0.35% |
| 2018 | 119.39 Million USD | 3467.31% |
| 2017 | 3.34 Million USD | -65.49% |
| 2016 | 9.69 Million USD | -78.14% |
| 2015 | 44.37 Million USD | -6.57% |
| 2014 | 47.49 Million USD | -46.82% |
| 2013 | 89.31 Million USD | 198.29% |
| 2012 | 29.94 Million USD | 124.73% |
| 2011 | 13.32 Million USD | -8.34% |
| 2010 | 14.53 Million USD | -32.08% |
| 2009 | 21.4 Million USD | -34.92% |
| 2008 | 32.88 Million USD | -47.58% |
| 2007 | 62.74 Million USD | 82.4% |
| 2006 | 34.4 Million USD | -38.58% |
| 2005 | 56 Million USD | 48.81% |
| 2004 | 37.63 Million USD | 15.05% |
| 2003 | 32.71 Million USD | 55.33% |
| 2002 | 21.06 Million USD | 4.97% |
| 2001 | 20.06 Million USD | 1.76% |
| 2000 | 19.71 Million USD | 325.67% |
| 1999 | 4.63 Million USD | 0.7% |
| 1998 | 4.6 Million USD | -60.68% |
| 1997 | 11.7 Million USD | 515.79% |
| 1996 | 1.9 Million USD | -52.5% |
| 1995 | 4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 30.1 Million USD | -7.11% |
| 2024 Q2 | 28.7 Million USD | -4.64% |
| 2023 FY | 32.4 Million USD | -14.62% |
| 2023 Q1 | 35.18 Million USD | -7.3% |
| 2023 Q4 | 32.4 Million USD | -10.13% |
| 2023 Q3 | 36.05 Million USD | -11.13% |
| 2023 Q2 | 40.57 Million USD | 15.32% |
| 2022 Q1 | 67.1 Million USD | -10.27% |
| 2022 Q3 | 48.09 Million USD | -7.17% |
| 2022 Q4 | 37.95 Million USD | -21.09% |
| 2022 FY | 37.95 Million USD | -49.25% |
| 2022 Q2 | 51.81 Million USD | -22.79% |
| 2021 Q2 | 90.86 Million USD | -33.13% |
| 2021 FY | 74.78 Million USD | -33.75% |
| 2021 Q4 | 74.78 Million USD | -11.83% |
| 2021 Q3 | 84.82 Million USD | -6.65% |
| 2021 Q1 | 135.89 Million USD | 20.38% |
| 2020 Q3 | 118.53 Million USD | -7.63% |
| 2020 Q4 | 112.88 Million USD | -4.76% |
| 2020 Q2 | 128.32 Million USD | 13.57% |
| 2020 FY | 112.88 Million USD | -5.12% |
| 2020 Q1 | 112.99 Million USD | -5.03% |
| 2019 FY | 118.97 Million USD | -0.35% |
| 2019 Q4 | 118.97 Million USD | 18.23% |
| 2019 Q1 | 111.62 Million USD | -6.51% |
| 2019 Q3 | 100.63 Million USD | -4.38% |
| 2019 Q2 | 105.24 Million USD | -5.72% |
| 2018 FY | 119.39 Million USD | 3467.31% |
| 2018 Q3 | 1.94 Million USD | -1.82% |
| 2018 Q4 | 119.39 Million USD | 6045.03% |
| 2018 Q1 | 2.96 Million USD | -11.35% |
| 2018 Q2 | 1.97 Million USD | -33.3% |
| 2017 Q2 | 5.82 Million USD | -50.24% |
| 2017 Q1 | 11.7 Million USD | 20.7% |
| 2017 FY | 3.34 Million USD | -65.49% |
| 2017 Q4 | 3.34 Million USD | -28.13% |
| 2017 Q3 | 4.65 Million USD | -20.05% |
| 2016 Q1 | 34.71 Million USD | -21.78% |
| 2016 FY | 9.69 Million USD | -78.14% |
| 2016 Q2 | 24.99 Million USD | -27.98% |
| 2016 Q4 | 9.69 Million USD | -40.98% |
| 2016 Q3 | 16.43 Million USD | -34.26% |
| 2015 Q1 | 38.12 Million USD | -19.74% |
| 2015 FY | 44.37 Million USD | -6.57% |
| 2015 Q2 | 28.2 Million USD | -26.03% |
| 2015 Q4 | 44.37 Million USD | -15.84% |
| 2015 Q3 | 52.73 Million USD | 86.99% |
| 2014 FY | 47.49 Million USD | -46.82% |
| 2014 Q3 | 58.3 Million USD | -16.07% |
| 2014 Q4 | 47.49 Million USD | -18.54% |
| 2014 Q2 | 69.47 Million USD | -12.61% |
| 2014 Q1 | 79.49 Million USD | -10.99% |
| 2013 Q1 | 29.16 Million USD | -2.61% |
| 2013 Q4 | 89.31 Million USD | 277.97% |
| 2013 Q3 | 23.63 Million USD | -30.31% |
| 2013 Q2 | 33.9 Million USD | 16.27% |
| 2013 FY | 89.31 Million USD | 198.29% |
| 2012 Q2 | 49.18 Million USD | -14.82% |
| 2012 FY | 29.94 Million USD | 124.73% |
| 2012 Q4 | 29.94 Million USD | -24.68% |
| 2012 Q3 | 39.75 Million USD | -19.17% |
| 2012 Q1 | 57.73 Million USD | 333.34% |
| 2011 FY | 13.32 Million USD | -8.34% |
| 2011 Q4 | 13.32 Million USD | -28.84% |
| 2011 Q3 | 18.72 Million USD | -25.84% |
| 2011 Q2 | 25.24 Million USD | -20.3% |
| 2011 Q1 | 31.68 Million USD | 117.93% |
| 2010 Q1 | 29.5 Million USD | 37.87% |
| 2010 Q4 | 14.53 Million USD | -24.67% |
| 2010 Q2 | 28.4 Million USD | -3.75% |
| 2010 Q3 | 19.29 Million USD | -32.06% |
| 2010 FY | 14.53 Million USD | -32.08% |
| 2009 FY | 21.4 Million USD | -34.92% |
| 2009 Q1 | 26.27 Million USD | -20.12% |
| 2009 Q2 | 29.94 Million USD | 13.97% |
| 2009 Q3 | 23.8 Million USD | -20.48% |
| 2009 Q4 | 21.4 Million USD | -10.11% |
| 2008 Q1 | 52.67 Million USD | -16.05% |
| 2008 Q2 | 44.61 Million USD | -15.29% |
| 2008 FY | 32.88 Million USD | -47.58% |
| 2008 Q3 | 39.64 Million USD | -11.14% |
| 2008 Q4 | 32.88 Million USD | -17.05% |
| 2007 Q4 | 62.74 Million USD | 48.16% |
| 2007 Q1 | 27.69 Million USD | -19.49% |
| 2007 Q2 | 49.07 Million USD | 77.18% |
| 2007 FY | 62.74 Million USD | 82.4% |
| 2007 Q3 | 42.34 Million USD | -13.71% |
| 2006 Q3 | 24.82 Million USD | -23.48% |
| 2006 FY | 34.4 Million USD | -38.58% |
| 2006 Q1 | 43.46 Million USD | -22.4% |
| 2006 Q2 | 32.43 Million USD | -25.37% |
| 2006 Q4 | 34.4 Million USD | 38.59% |
| 2005 Q3 | 55.41 Million USD | 15.38% |
| 2005 Q4 | 56 Million USD | 1.08% |
| 2005 Q2 | 48.02 Million USD | -15.41% |
| 2005 Q1 | 56.77 Million USD | 50.85% |
| 2005 FY | 56 Million USD | 48.81% |
| 2004 FY | 37.63 Million USD | 15.05% |
| 2004 Q4 | 37.63 Million USD | -4.94% |
| 2004 Q3 | 39.59 Million USD | -13.39% |
| 2004 Q2 | 45.71 Million USD | 67.98% |
| 2004 Q1 | 27.21 Million USD | -16.82% |
| 2003 Q3 | 38.98 Million USD | 3.38% |
| 2003 Q2 | 37.7 Million USD | 133.63% |
| 2003 Q4 | 32.71 Million USD | -16.07% |
| 2003 FY | 32.71 Million USD | 55.33% |
| 2003 Q1 | 16.14 Million USD | -23.37% |
| 2002 Q4 | 21.06 Million USD | 59.95% |
| 2002 FY | 21.06 Million USD | 4.97% |
| 2002 Q2 | 16.47 Million USD | -18.63% |
| 2002 Q1 | 20.25 Million USD | 0.93% |
| 2002 Q3 | 13.16 Million USD | -20.09% |
| 2001 Q2 | 14.67 Million USD | -13.09% |
| 2001 Q1 | 16.88 Million USD | -14.36% |
| 2001 Q3 | 12.16 Million USD | -17.08% |
| 2001 Q4 | 20.06 Million USD | 64.9% |
| 2001 FY | 20.06 Million USD | 1.76% |
| 2000 Q2 | 23.25 Million USD | -6.05% |
| 2000 Q1 | 24.75 Million USD | 434.39% |
| 2000 Q4 | 19.71 Million USD | -12.05% |
| 2000 Q3 | 22.41 Million USD | -3.59% |
| 2000 FY | 19.71 Million USD | 325.67% |
| 1999 FY | 4.63 Million USD | 0.7% |
| 1999 Q1 | 3.6 Million USD | -21.74% |
| 1999 Q2 | 3.2 Million USD | -11.11% |
| 1999 Q3 | 4.2 Million USD | 31.25% |
| 1999 Q4 | 4.63 Million USD | 10.29% |
| 1998 FY | 4.6 Million USD | -60.68% |
| 1998 Q4 | 4.6 Million USD | -23.33% |
| 1998 Q3 | 6 Million USD | -16.67% |
| 1998 Q2 | 7.2 Million USD | -25.77% |
| 1998 Q1 | 9.7 Million USD | -17.09% |
| 1997 Q2 | 1.8 Million USD | -21.74% |
| 1997 FY | 11.7 Million USD | 515.79% |
| 1997 Q4 | 11.7 Million USD | 303.45% |
| 1997 Q3 | 2.9 Million USD | 61.11% |
| 1997 Q1 | 2.3 Million USD | 21.05% |
| 1996 Q4 | 1.9 Million USD | -26.92% |
| 1996 Q1 | 3.6 Million USD | -10.0% |
| 1996 Q3 | 2.6 Million USD | -18.75% |
| 1996 FY | 1.9 Million USD | -52.5% |
| 1996 Q2 | 3.2 Million USD | -11.11% |
| 1995 FY | 4 Million USD | 0.0% |
| 1995 Q4 | 4 Million USD | 0.0% |
| 1995 Q2 | 800 Thousand USD | 700.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -1402757.143% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1554.896% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -207.049% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -5769.376% |
| Rebus Holdings, Inc. | 5000.00 USD | -648020.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 75.113% |
| Qrons Inc. | 420.00 USD | -7715614.286% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -4105.054% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -15.968% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -6643.425% |
| Skye Bioscience, Inc. | 11.94 Million USD | -171.398% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 16.58% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -348.851% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -42341.784% |
| SQZ Biotechnologies Company | 107.18 Million USD | 69.767% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -2162.938% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -44681.317% |
| Mesoblast Limited | 667.9 Million USD | 95.148% |
| Marizyme, Inc. | 22.01 Million USD | -47.199% |
| Genus plc | 1.02 Billion USD | 96.85% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2285.683% |
| Pharming Group N.V. | 462.85 Million USD | 92.999% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -878.143% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -6393.681% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -5068.421% |
| ContraFect Corporation | 20.67 Million USD | -56.71% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -8201.44% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -8379.317% |
| IMV Inc. | 31.33 Million USD | -3.422% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -681.617% |
| MultiCell Technologies, Inc. | 126.22 USD | -25674119.617% |
| ONE Bio Corp. | 70.08 Million USD | 53.762% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -3348.588% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 74.783% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -7406.358% |
| Q BioMed Inc. | 3.51 Million USD | -821.799% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 7.883% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -12302.929% |
| Biomind Labs Inc. | 73.81 Thousand USD | -43799.267% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 92.739% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2136.681% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -7.966% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1079.973% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -4613.696% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1144.854% |
| GB Sciences, Inc. | 103.44 Thousand USD | -31227.701% |
| Alpha Cognition Inc. | 2.45 Million USD | -1221.523% |
| HST Global, Inc. | 1526.00 USD | -2123491.088% |
| CSL Limited | 38.02 Billion USD | 99.915% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -3180.069% |
| Halberd Corporation | 10.13 Thousand USD | -319769.707% |
| Enzolytics Inc. | 361.7 Million USD | 91.041% |
| Agentix Corp. | 261.39 Thousand USD | -12297.472% |
| Resverlogix Corp. | 8.11 Million USD | -299.335% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1625.669% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.287% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 32.066% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -4966.161% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -142150.121% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -262.112% |
| AVAX Technologies, Inc. | 7.37 Million USD | -339.275% |
| Zenith Capital Corp. | 7410.00 USD | -437227.935% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.043% |
| Ember Therapeutics, Inc. | 184.00 USD | -17611856.522% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -9970.042% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -12298.8% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -3392.173% |
| Kadimastem Ltd | 2.3 Million USD | -1306.462% |
| Helix BioMedix, Inc. | 3.02 Million USD | -971.242% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 38.51% |
| BioStem Technologies, Inc. | 14.56 Million USD | -122.564% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -56659.029% |
| LadRx Corporation | 2.3 Million USD | -1304.145% |
| Cell Source, Inc. | 195.17 Thousand USD | -16503.901% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9064.152% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9064.152% |
| NovAccess Global Inc. | 62.24 Thousand USD | -51959.504% |
| Affymax, Inc. | 7.44 Million USD | -335.389% |
| Itoco Inc. | 1.4 Million USD | -2214.595% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -33777.291% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -30471.698% |
| Mobile Lads Corp. | 52.00 USD | -62319130.769% |
| CytoDyn Inc. | 11.13 Million USD | -191.002% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -22565.977% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -181141.611% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -8306.858% |
| SYBLEU INC | 330.46 Thousand USD | -9706.093% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -7815.061% |
| International Stem Cell Corporation | 5.39 Million USD | -501.224% |
| Bioxytran, Inc. | 137.63 Thousand USD | -23444.37% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -116.014% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -95.464% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -40920.253% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -3647.758% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -331.103% |
| Neutra Corp. | 2851.00 USD | -1136553.806% |
| PureTech Health plc | 693.97 Million USD | 95.33% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -301.507% |
| IXICO plc | 15.84 Million USD | -104.533% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -291.282% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 68.637% |
| CSL Limited | 38.02 Billion USD | 99.915% |
| Cellectis S.A. | 333.99 Million USD | 90.297% |